FDA approves second Reykjavik manufacturing suite for AVT02

Ractigen Therapeutics reports positive first-in-human data for RAG-18 in Duchenne muscular dystrophy

AnnJi Pharmaceutical's AJ201 advances into pivotal Phase 3 trial for SBMA

Teva reports new ecopipam data showing tic reduction in Tourette syndrome

PearlMatrix P-15 Peptide Enhanced Bone Graft receives Medicare New Technology Add-on Payment (NTAP) status

Genentech's fenebrutinib receives FDA priority review for multiple sclerosis

DBV Technologies submits FDA application for VIASKIN Peanut Patch in children

UTR Therapeutics' UTRxMYCN M1-14 receives US FDA Orphan Drug Designation and Rare Pediatric Disease Designation

Vanda Pharmaceuticals reports positive Phase III results for HETLIOZ in Delayed Sleep-Wake Phase Disorder

Egetis Therapeutics receives FDA approval for EMCITATE in MCT8 deficiency

AstraZeneca invests USD2bn in Summit Therapeutics to advance ADC and cancer-drug combinations

BRC Therapeutics participates in regulators' workshop advancing botanical drug development

Lupin announces receipt of US FDA tentative approval for Apixaban Oral Suspension

QIAGEN completes US QIAstat-Dx bloodstream infection portfolio with FDA clearance

Innovent expands global Phase 3 study of IBI363/TAK-928 to include non-squamous NSCLC